Leerink Swann's Paul Matteis just reiterated his 'buy' rating on shares of GW Pharmaceuticals Plc (NASDAQ:GWPH) alongside a price target of $157.00 per share. His previous price target was $153.00 per share, and GW Pharma currently has an average price target of $171.33 per share.
With a last trade price of $126.48 for shares of GW Pharma, this price target represents over 24% potential upside. Yesterday, the company announced financial results for the first quarter ended the 31st of December, 2017.
"With the Epidiolex regulatory applications accepted for review in both the US and Europe, and an assigned mid-year FDA decision date, 2018 is expected to be an exciting year for our Company with an anticipated first U.S. approval and launch. The commercial teams are making great progress toward launching Epidiolex with full conviction," stated Justin Gover, GW's Chief Executive Officer.
Want analyst alerts in your inbox as they're released?
Sign up for D/M/O Pro Analyst Updates here.
To sign up for GW Pharma updates, click here. Be sure to subscribe to one or more of our free e-mail newsletters so you stay up-to-date on important marijuana stock updates. Also, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!